SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Teva Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: grannylu who wrote (245)8/15/1998 12:29:00 AM
From: Doug  Respond to of 340
 
grannylu: It was so good of you to spare the time and share that personal testimony on the effectiveness of Copaxone.

I hope your Daughter's condition remains stable and improves.




To: grannylu who wrote (245)8/15/1998 2:01:00 AM
From: rkrw  Read Replies (1) | Respond to of 340
 
To reiterate what you stated, Copaxone is the lone MS drug to have proven thats its efficacy does not deteriorate in time, actually slightly increases. I am not sure how far out their data goes, maybe 2-3 year studies. The BGEN and Chiron beta interferon drugs have been proven to begin to lose effectiveness as soon as a year after therapy begins. Long term, this should help Teva.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News